MedTrace Logo

Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer

NCT03784755 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 409

Last updated 2026-03-27

No results posted yet for this study

Summary

The purpose of this study is to compare the effects of ablative therapy (radiation or surgery) to all sites of disease combined with standard treatments on prostate cancer, compared to the standard or usual treatments used to treat this disease.

Conditions

  • Prostate Cancer Metastatic

Interventions

RADIATION

Ablative Radiation Therapy

Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).

OTHER

Standard of care

Patients continue to receive their current planned systemic therapy at the discretion of the treating physician

Sponsors & Collaborators

  • Canadian Cancer Society (CCS)

    collaborator OTHER

  • Canadian Cancer Trials Group

    lead NETWORK

Principal Investigators

  • Patrick CF Cheung · Odette Cancer Centre, Sunnybrook Health Science Centre, Toronto, ON Canada

  • M. Tamim Niazi · The Jewish General Hospital, Montreal, QC Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2032-12-31
Completion
2033-07-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03784755 on ClinicalTrials.gov